Progyny's stock experienced a significant post-market plunge of 8.76% on Thursday, following the release of its latest financial results and forward guidance.

The sharp decline was primarily driven by investor concerns over the company's growth trajectory. While Progyny reported better-than-expected fourth-quarter 2025 revenue, its outlook for fiscal year 2026 projects a slowdown in revenue growth to a range of 5.1% to 9%, compared to 10% growth in 2025. Additionally, first-quarter 2026 revenue growth guidance of just 2.5% fell well below analyst expectations.

Further contributing to the negative sentiment was the confirmed loss of a large client that did not renew for 2025, resulting in no revenue contribution in the fourth quarter. The company's pharmacy benefit services segment also reported a 1.1% revenue decline during the quarter, adding to concerns about future growth prospects across its business lines.